He also established the UK National Health Service National Amyloidosis Centre, funded by the UK Department of Health, to provide diagnostic and management advisory services for the whole national caseload, and which also sees many patients from abroad. There are more than 4,000 patient visits per year. His research has been continuously supported by the Medical Research Council, with more than £18 million since1969, and he has also received generous support from the Wolfson Foundation, the Wellcome Trust and other medical charities. He is a Fellow of the Royal Society, a Founder Fellow of the Academy of Medical Sciences, and has been a member of the Councils of both academies. In 2007 he was the Harveian Orator of the Royal College of Physicians and also received the Royal Society Glaxo Smith Kline Prize. In 2008 he received the Ernst Chain Prize for medical discovery. In2011 he retired as Head of Medicine at the Royal Free Campus of UCL in order to become the first Director of the new UCL Wolfson Drug Discovery Unit, created with Wolfson Foundation support. Core funding of the Unit, renewed until 2022, is from the National Institute for Health Research via the UCLH/UCL Biomedical Research Centre, which is also funding the DESPIAD clinical trial of his drug for Alzheimer’s disease. He was created Knight Bachelor for Services to Biomedicine in the 2012 New Year Honours and in 2014 was elected to Honorary Fellowship of his alma mater, Trinity College, Cambridge.